Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deudextromethorphan - Avanir Pharmaceuticals

Next Previous
Search
Drug Profile

Deudextromethorphan - Avanir Pharmaceuticals

Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Antitussives; Behavioural disorder therapies; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P-450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Agitation
  • Phase II/III Schizophrenia
  • Phase II Impulse control disorders; Major depressive disorder; Neurodegenerative disorders
  • No development reported Neuropathic pain; Psychiatric disorders

Most Recent Events

  • 29 Jan 2025 Avanir Pharmaceuticals terminates a phase III trial in Agitation (In adults, In the elderly) in the USA, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Ireland, Mexico, Netherlands, Slovakia, Slovenia and Spain (PO, Capsule) as the AVP 786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention (NCT04464564)
  • 20 Jan 2025 Avanir terminates a phase III trial in Agitation (In adults, In the elderly) in USA, Bulgaria, Canada, Czech Republic, France, Hungary, Italy, Poland, South Africa, Spain (PO) as the AVP 786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention (NCT02446132)
  • 22 May 2024 Otsuka Pharmaceutical terminates development of Deudextromethorphan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top